Although it was previously known that BBR could inhibit MAO activity (with an IC50 of 126 μmol L−1 for MAO-A and 98.4 μmol L−1 for MAO-B), the results of this study put into perspective the usability of BBR as a MAO-inhibitor for PD treatment [23,31,32]. Here, MAOB is linked to Parkinson disease.